Search

everythinglearnresearchcommunity

for

Search:↓

User asks if breaking open Eucapil (fluridil) ampule and using half is okay, and if leaving open vile overnight ruins it.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The ineffectiveness of Strut Health's dutasteride capsules, which are filled with raw powder instead of liquid and don't contain any buffering agents that would allow for absorption into the bloodstream. It is suggested to use other brands of liquid-filled dutasteride capsules for better results.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

The conversation discusses unconventional and satirical ideas for hair regrowth, including using umbilical cord cells, stem cells, and other humorous suggestions. It concludes with recommendations for more traditional methods like hair transplants or hair systems.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.